Engineered 'Smart Cells' target deadly lung scarring in pioneering trial
NCT ID NCT07329959
Summary
This early-stage trial is testing a new cell therapy for people with severe, end-stage idiopathic pulmonary fibrosis (IPF), a fatal lung-scarring disease. Doctors will give patients specially engineered immune cells designed to find and calm the scar tissue in the lungs. The main goals are to see if this one-time treatment is safe and if it can help slow down the disease in patients who have no other options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.